A multigene prognostic assay for selection of adjuvant chemotherapy in patients with T3, stage II colon cancer: impact on quality-adjusted life expectancy and costs.

Publication Type:

Journal Article


Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, Volume 15, Issue 8, p.1014-21 (2012)


Antineoplastic Combined Chemotherapy Protocols, Chemotherapy, Adjuvant, Colonic Neoplasms, Cost-Benefit Analysis, Humans, Life Expectancy, Markov Chains, Neoplasm Recurrence, Local, Neoplasm Staging, Prognosis, Quality-Adjusted Life Years, United States


Uncertainty exists regarding appropriate and affordable use of adjuvant chemotherapy in stage II colon cancer (T3, proficient DNA mismatch repair). This study aimed to estimate the effectiveness and costs from a US societal perspective of a multigene recurrence score (RS) assay for patients recently diagnosed with stage II colon cancer (T3, proficient DNA mismatch repair) eligible for adjuvant chemotherapy.